SCHEMBL24323544

SCHEMBL24323544

C[C@H]1CCCCCN1C(=O)[C@H](N)CCCN=C(N)N

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 9/20 0.63
DPP8 Q6V1X1 5/20 0.51
DPP9 Q86TI2 4/20 0.51
DPP7 Q9UHL4 8/20 0.47
ARG1 P05089 1/20 0.46
CYP1A2 P05177 1/20 0.46
GLA P06280 1/20 0.46
TSHR P16473 1/20 0.46
NFKB1 P19838 1/20 0.46
APEX1 P27695 1/20 0.46
CYP2C19 P33261 1/20 0.46
NOS2 P35228 1/20 0.46
CHRM2 P08172 1/20 0.45
CHRM4 P08173 1/20 0.45
CHRM1 P11229 1/20 0.45
F2 P00734 1/20 0.44
FAP Q12884 2/20 0.43
MC4R P32245 1/20 0.40
MC3R P41968 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29390523 0.79 DPP4 (0.68) DPP4DPP8DPP9CYP1A2GLA
SCHEMBL19981831 0.78 DPP4 (0.61) DPP4DPP8DPP9DPP7FAP
SCHEMBL30277613 0.78 DPP4 (1.00) DPP4DPP8DPP9DPP7FAP
SCHEMBL24324253 0.76 DPP4 (0.55) DPP4DPP8DPP9DPP7ARG1
SCHEMBL24322510 0.76 DPP4 (0.55) DPP4DPP8DPP9DPP7ARG1
SCHEMBL12709891 0.75 DPP7 (0.59) DPP4DPP8DPP9DPP7TSHR
SCHEMBL24323563 0.75 DPP4 (0.54) DPP4DPP8DPP9F2
SCHEMBL29350954 0.75 DPP4 (0.63) DPP4DPP8DPP9CYP1A2GLA
SCHEMBL18774976 0.73 DPP4 (0.61) DPP4DPP8DPP9DPP7TSHR
SCHEMBL18774982 0.73 DPP4 (0.61) DPP4DPP8DPP9DPP7TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220122691-A1 HtrA Inhibitors and CagA Inhibitors and Use Thereof Psomagen Inc. (US) 2022-04-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220122691-A1 HtrA Inhibitors and CagA Inhibitors and Use Thereof HTRA1, GIPR, HPN DPP4 532/4885DPP8 296/4885DPP9 138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.